|
|
|
| Comparative study of Oxycodone or Sufentanil combined with Etomidate for anesthesia induction in patients with moyamoya disease |
| ZHAO Shuang1,2 YU Yingqun2 WANG Baoguo1▲ |
1.Department of Anesthesiology, Sanbo Brain Hospital, Capital Medical University, Beijing 100093, China;
2.Department of Anesthesiology, Nanyuan District, the Fifth Medical Center, General Hospital of Chinese People’s Liberation Army, Beijing 100071, China |
|
|
|
Abstract Objective To investigate the hemodynamic changes and anesthesia quality of patients with moyamoya disease treated with equivalent dose of Oxycodone and Sufentanil combined with Etomidate during anesthesia induction. Methods A total of 80 patients with moyamoya disease who admitted to Nanyuan District, the Fifth Medical Center, General Hospital of Chinese People’s Liberation Army from May to November 2019 were selected as study objects. They were divided into Oxycodone group (OX group) and Sufentanil group (SF group), with 40 cases in each group. After entering the operating room, venous access was established and invasive arterial monitoring was performed. Anesthesia induction: Oxycodone Hydrochloride Injection 0.25 mg/kg was injected intravenously in OX group, and Sufentanil Citrate Injection 0.25 μg/kg was injected intravenously in SF group, cough, muscle spasm, and respiratory depression were observed within two minutes. Then, Etomidate 0.3 mg/kg, Midazolam 2 mg, Penehyclidine Hydrochloride 0.3 mg, Granisetron 3 mg and Rocuronium 0.6 mg/kg were injected intravenously in both groups. After the patients were fully relaxed, laryngeal mask was inserted and mechanical ventilation was performed. Heart rate (HR) and mean arterial pressure (MAP) were observed and recorded before anesthesia induction (T0), two minutes after Oxycodone/Sufentanil injection (T1), before laryngeal mask implantation (T2), immediately after laryngeal mask implantation (T3) and one minutes after laryngeal mask implantation (T4). Results The incidence of cough in OX group was lower than that in SF group, and the difference was statistically significant (P < 0.05). There were no significant differences in the incidence of dizziness and nausea, and respiratory depression between two groups (P > 0.05). In SF group, HR and MAP at T1 were higher than those at T0, and the differences were statistically significant (P < 0.05). HR and MAP at T1 in OX group were lower than those in SF group, and the differences were statistically significant (P < 0.05), but there were no significant differences between HR and MAP in two groups at other time points (P > 0.05). Conclusion The effect of Oxycodone combined with Etomidate on anesthesia induction of moyamoya disease is safe and reliable, and the incidence of adverse reactions is lower than Sufentanil induction, and the hemodynamics is stable.
|
|
|
|
|
|
[1] Suzuki J，Takaku A. Cerebrovascular“moyamoya” disease. Disease showing abnormal net-like vessels in base of brain [J]. Arch Neurol，1969，20（3）：288-299.
[2] 叶挺，韩聪，段炼.儿童烟雾综合征的临床特征及外科手术疗效[J].中国脑血管病杂志，2015，12（1）：12-16.
[3] 李锦，张雪梅，程灏，等.神经外科麻醉后恢复期常见病症及处理[J].中华神经外科杂志，2010，26（9）：816-818.
[4] Kronenburg A，Braun KP，Van Der Zwan A，et al. Recent advances in moyamoya disease：pathophysiology and treatment [J]. Curr Neurol Neurosci Rep，2014，14（1）：423.
[5] Gosalakkai JA. Moyamoya disease：a review [J]. Neurol India，2002，50（1）：6-10.
[6] Brown SC，Lam AM. Moyamoya disease：a review of clinical experience and anaesthetic management [J]. Can J Anaesth，1987，34（1）：71-75.
[7] Osanai T，Kuroda S，Nakayama N，et al. Moyamoya disease presenting with subarachnoid hemorrhage ocalized over the frontal cortex：case report [J]. Surg Neurol，2008，69（2）：197-200.
[8] Mutsmasa T. Magnification angiography in moyamoya disease：New observations on collateral vessels [J]. Radiology，1980，136（2）：379-386.
[9] Fujimura M，Shimizu H，Inoue T，et al. Significance of focal cerebral hyperperfusion as a cause of transient neurologic deterioration after extracranial-intracranial bypass for moyamoya disease：comparative study with non-moyamoya patients using N-isopropyl-p-[123I] iodoamphetamine single-photon emission computed tomography [J]. Neurosurgery，2011，68（4）：957-964.
[10] 裴皓，罗爱林.舒芬太尼药理作用与临床应用[J].医药导报，2009，28（11）：1482-1485.
[11] Zhao Y，Wu XM，Duan JL，et al. Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients [J]. Chin Med J，2009，122（3）：291-295.
[12] 刘鲲鹏，孙海涛，薛富善，等.不同剂量舒芬太尼预处理对大鼠的延迟性心肌保护作用[J].中华麻醉学杂志，2009，29（5）：405-408.
[13] 许智鸿，潘艳，廖庆武.舒芬太尼诱发呛咳反应机制及预防用药的研究进展[J].中国临床医学，2019，26（6）：951-954.
[14] Bailey PL. Possible mechanism（s）of opioid-induced coughing [J]. Anesthesiology，1999，90（1）：335.
[15] 张志永，黄宇光.芬太尼咳嗽反射的研究及其治疗进展[J].临床麻醉学杂志，2007，23（1）：84-85.
[16] 张瑞冬，陈锡明，陈煜.芬太尼诱发呛咳的机制、影响因素和预防[J].国际麻醉学与复苏杂志，2006，27（6）：369-372.
[17] 王涛涛，翟明，郭睿，等.盐酸纳美芬对心脏手术全麻诱导期舒芬太尼诱发呛咳的预防作用[J].蚌埠医学院学报，2017，42（4）：454-457，461.
[18] Lalovic B，Kharasch E，Hoffer C，et al. Pharmacoki-netics and pharmacodynamics of oral oxycodone in healthy human subjects：role of circulating active metabolites [J]. Clin Pharmacol Ther，2013，79（5）：461-479.
[19] Peckham EM，Traynor JR. Comparison of the antinoci-ceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats [J]. J Pharmacol Exp Ther，2012，316（3）：1195-1201.
[20] Narita M，Nakamura A，Ozaki M，et al. Comparative pharma eological profiles of morphine and oxycodone under a neuropathie pain-like state in mice：evidence for less sensitivity to morphine [J]. Neuropsyehopharmaeology，2011，33（5）：1097-1112.
[21] Kalso E，P?觟yhi?覿 R，Onnela P，et al. Intravenous morphine and oxycodone for pain after abdominal surgery [J]. Acta Anaesthesiol Scand，1991，35（7）：642-646. DOI：10.1111/j.1399-6576.1991.tb03364.x.
[22] 熊国强，贾军，黄仁健，等.异丙酚和依托咪酯在颅脑手术中的脑保护作用[J].实用神经疾病杂志，2005，8（4）：13-14.
[23] 陈珍爱，赵崇汉，严恺舒.不同剂量依托咪酯复合舒芬太尼在老年颅脑手术麻醉诱导中的应用[J].中外医学研究，2020，18（18）：118-119.
[24] 陈伟，陈鹏，张毅，等.依托咪酯用于颅脑手术麻醉的可行性与安全性[J].中国医药指南，2012，10（20）：423-424.
[25] 张辉，王钟兴，刘克玄，等.比较不同剂量舒芬太尼全麻诱导对喉罩置入时心血管反应的影响[J].中华生物医学工程杂志，2008，14（4）：294-296.
[26] 徐建国.盐酸羟考酮的药理学和临床应用[J].临床麻醉学杂志，2014，30（5）：511-513. |
|
|
|
